MLFC has been recently awarded several research studies for patients. Discounted fertility medication and some free lab services are available for patients who qualify for certain studies.

For more information,  please contact our Study Patient Coordinator – Eileen Davies –  at 484-380-4861 or email at daviese@mainlinefertility.com

1. The Eeva® array-Comparative Genomic Hybridization (aCGH) Study is currently recruiting patients at Main Line Fertility

Eeva scopeEeva: The Early Embryo Viability Assessment Test, is a test to be used by IVF laboratories to analyze early embryo development.  At the heart of the Eeva System is software that was designed to assess critical differences in early embryo growth and determine an embryo’s viability and the potential for further development.The Eeva Test was developed based on landmark research conducted at Stanford University1 which discovered that early embryo growth events can predict embryo development and reflect the underlying health of the embryo.

The goal of the Eeva aCGH Study is to collect imaging data on embryos followed to blastocyst stage (Day 5-6) and correlate Eeva parameters with array – Comparative Genomic Hybridization(aCGH) results and ongoing pregnancy rates.

 

The key patient eligibility criteria include but are not limited to:

  • Women undergoing IVF treatment with array-Comparative Genomic Hybridization (aCGH) testing
  • Women ≤ 43 years old
  • Fertilization using only ejaculated sperm (fresh or frozen)
  • Willing to have all fertilized eggs (2PN=2 pronuclei) imaged by Eeva
  • Willing to provide written informed consent

If you are interested in participating in this research study, please contact Eileen Davies, Study Coordinator at (484) 380-4861 or daviese@mainlinefertility.com for more information.

Eeva is an investigational device.  Limited by United States law to investigational use.

  •   Wong et al. in Nature Biotechnology, 2010.
  •   Conaghan et al.  Fertility &Sterility, May 2013

2. AFOLIA (IVY) IVF Study – Stimulation Study for IVF Patients

 For more information,  please contact our Study Patient Coordinator – Eileen Davies –  at 484-380-4861 or email at daviese@mainlinefertility.com

 3. Free embryo PGD for Single Gene Disease

Carrier Screening is when a couple is tested to see if one or both is a carrier for a genetic disease.  Testing involves taking a blood sample and sending it to a genetic testing laboratory called Good Start Genetics. If the report from Good Start Genetics indicates that both are carriers for the same genetic disease, patients may be eligible to receive free pre-implantation genetic diagnosis (PGD) of their embryos after IVF for the single gene disease.  For more information about carrier screening visit https://www.goodstartgenetics.com/carrier-screening/ For more information about this free PGD eligibility, contact Eileen Davies at daviese@mainlinefertility.com

4.  IVF Clinical Trial

 Are you currently trying to conceive and:

  • Planning to have an IVF cycle?
  • Are between the ages of 25 and 40?
  • Not had more than one failed IVF cycle?

Then you may be eligible to participate in an IVF Study with Preimplantation Genetic Screening (PGS)

Main Line Fertility Center is participating in a multi-center, international study designed to evaluate pregnancy outcomes in patients undergoing IVF with a single embryo transfer. The purpose of the study is to determine if biopsy and genetic testing of an embryo (PGS) results in a better outcome than the standard method of selecting an embryo based on how well it is growing.

In this study, there are two groups to which patients are assigned:

  • In one group, all the embryos that are developing normally 5 & 6 days after egg retrieval undergo screening for chromosomal abnormalities using a test called VeriSeq PGS. Participants will not be charged for the VeriSeq PGS.
  • In the other group, the best embryo is selected by standard screening methods and does not undergo VeriSeq PGS. All other embryos are tested with PGS.

Both groups have embryos frozen 5-6 days after the egg retrieval and will then undergo a frozen embryo transfer:

Study participant will be offered a blood test after 10 weeks gestation called an NIPT test (Non-Invasive Pre-Natal Testing) which will screen for chromosomal abnormalities commonly found in pregnancies such as Down Syndrome. Participants will not be charged for the NIPT test.

The benefits of the study are:

  • The embryos in both groups that have been tested but not transferred could be available for transfer in a future non-study cycle.
  • The study will help future patients to know how much Pre-Implantation Genetic Screening with VeriSeq improves their chances of having a healthy baby

Your decision to participate in the study is voluntary and deciding not to participate will not change your care at Main Line Fertility Center.

Please Contact:

Eileen B. Davies

Clinical Research Coordinator

484-380-4861 or daviese@mainlinefertility.com

 

 5.  IIT Preimplantation Genetic Screening (PGS)/Eeva Study for IVF patients – starting around April 2015.

In 2015 Main Line Fertility will be conducting an investigator-initiated trial (IIT) in which the relationship between PGS and time-lapse videography of embryos in two different standard controlled ovarian stimulation (COS) protocols will be compared.  Inclusion criteria include: IVF patients between the ages of 21-38,  FSH<10 IU/ml on day 2-4 of menstrual cycle, anti-mullerian hormone (AMH) > 1.5, basal antral follicle number between 12 and 20 on day 2-4, BMI between 18 and 32, greater than 8 fertilized eggs after ICSI.  Exclusion criteria are the following: smokers, polycystic ovarian disease (PCOS), testicular aspirated sperm, PGD for single genes, PGS banking cycles.  Fertilization will be by intra-cytoplasmic sperm injection (ICSI), and all blastocyst embryos will be biopsied for PGS and then cryopreserved for a future frozen embryo transfer (FET) cycle/s.  Eligible patients will receive most of the fertility medication (FSH/LH) at no cost, and eligible patients will receive 50% discount for PGS.  Patients must be screened for eligibility by study coordinator Eileen Davies before enrollment into this study.  Screening for this study might begin in April 2015, at the earliest….. after IRB approval.

6.  THRIVE In Vitro Fertilization (IVF) Research Study

Main Line Fertility is currently seeking patients for the Thrive-IVF Research Study. The study is evaluating the efficacy, safety, and tolerability of NT100, an investigational medicine in women who have had repeated IVF failures despite having good-quality embryos. NT100 is a novel treatment that is being evaluated to determine if it improves the chances of getting pregnant after IVF.

For more information about NT100, visit www.noratherapeutics.com

You may be eligible for the Thrive-IVF Research Study if you:

  • Are between 21 and 38 years of age
  • Have had 3 or more failed IVF cycles that included transfer of good-quality embryos (at least 2 of these involving the transfer of fresh embryos)

If you are interested in learning more about the Thrive-IVF Research Study and whether you may be eligible to participate, please contact Eileen Davies, at 484-380-4861  or email at daviese@mainlinefertility.com

 

7. Vanishing Twin Study

  • ages 18 or older
  • Clincial confirmed vanishing twin pregnancy
  • Did not use egg donor

8.  LUTREPULSE hypogonadotropic hypogonadism non-IVF study

Main Line Fertility Center is participating in the LutrePulse Clinical Research Study for women between the ages of 18-40 who have been diagnosed with primary amenorrhea with hypogonadotropic hypogonadism, and have a desire to become pregnant.  To learn more about the study and determine if you may be eligible to participate in the study, please contact the Study Coordinator Eileen Davies at 484-380-4861 or via email at Eileen.davies@mainlinefertility.com

  • ages 18-40 years of age
  • Diagnosed with hypogonadotropic hypogonadism
  • Normal uterine cavity diagnosed by HSG or laparoscopy

 9. Egg Freezing Study:

MLFC is currently enrolling patients in our egg freezing study. Qualified patients will receive free fertility medication and a $2000 discount for IVF services. IVF patients must be between the ages of 21 and 37. Day 3 FSH must be less than 10 IU/ml. CLOSED as of May 1, 2013

10. Biomarker study:

MLFC has been approved for a study evaluating certain substances that are found in follicular fluid and are released by embryos during incubation in the laboratory.  Patients who are undergoing IVF and who qualify will receive a $1000 discount off their IVF cycle.  Women must between the ages of 18 and 37, have an FSH less than 12, and have no more than one previous cycle of IVF.  Women who have diabetes, polycystic ovary syndrome (PCOS), and endometriosis do not qualify for this study. CLOSED.

11. Ovarian Stimulation Study for IVF patients:

MLFC is currently enrolling IVF patients into a study that compares  two different ovarian stimulation protocols. Patients must be between 21-40 (inclusive) years of age. Free fertility stimulation medication is available for those who qualify.  Day 3 FSH must be less than 10 IU/ml and AMH must be greater or equal to 1.0. CLOSED JUNE 2, 2014